#United States #North Carolina #Floreo #VR Therapy #neurodivergent

North Carolina's Medicaid Waiver for VR Therapy

North Carolina has taken a significant step forward in supporting its neurodivergent community by approving the reimbursement of virtual reality (VR) therapy through its Medicaid NC Innovations Waiver. This initiative, which partners with Floreo, a leading developer of VR-based therapeutic solutions, aims to provide essential services to individuals with intellectual and developmental disabilities.

The NC Innovations Waiver is designed to enhance access to various home and community-based supports, which span from daily living assistance and job coaching to technology aids and caregiver support. By waiving certain Medicaid eligibility criteria, such as income considerations, the program becomes accessible to all North Carolinians diagnosed with autism or other developmental disabilities, offering them an opportunity for enhanced quality of life.

Vijay Ravindran, Floreo’s CEO and founder, praised the state’s initiative, stating, "North Carolina's commitment to providing practical support for the neurodivergent community is evident in this expansion. Many individuals will now have a new avenue for gaining confidence in their daily activities." Through the partnership with Floreo, eligible families within the seven-county region managed by Alliance Health—Cumberland, Durham, Harnett, Johnston, Mecklenburg, Orange, and Wake—can request reimbursement directly from their care managers.

Floreo’s VR platform provides immersive scenarios that empower neurodivergent children and adults to practice vital social and life skills. Users can navigate everyday challenges such as public transportation, interactions with law enforcement, and classroom participation in a controlled virtual environment. This innovative approach replaces traditional methods, offering a safe and engaging way to build essential skills necessary for independence and social interaction.

Currently, North Carolina joins a growing fleet of states—like Tennessee, New York, and Wisconsin—who recognize the value of Floreo's VR therapy by including it within their Medicaid waiver reimbursements. Floreo is also notable for being the first VR autism technology recognized as a breakthrough device by the Food and Drug Administration (FDA), reflecting its efficacy and potential impact on improving the lives of neurodivergent individuals.

Research conducted in collaboration with esteemed institutions, including the Center for Autism Research at The Children's Hospital of Philadelphia and the National Institutes of Health, continues to validate the positive outcomes associated with Floreo's VR therapy. Their curriculum not only complements traditional therapeutic approaches but also leads to better results for individuals with developmental disabilities.

Families interested in incorporating Floreo’s services into their support plans can reach out to their care managers for further guidance. This progressive move not only showcases North Carolina's dedication to supporting neurodivergent individuals but also sets an exemplary model for other states looking to enhance their healthcare offerings through innovative technology solutions.

For more information about Floreo and its VR therapy offerings, please visit floreovr.com.